

ASH 2013 Annual Meeting
December 7-10; New Orleans Convention Center
University of Chicago Medicine Comprehensive Cancer Center Presentations

Day	Author First Name	Author Last Name	Senior Author (if not presenting)	Location	Session Start	Session End	Talk Start	Talk End	Talk Order	Session Number	Session Title	Session Type	Poster/Talk Number	Presentation Title
Friday 12/6	Lucy	Godley		Sheraton New Orleans Rhythms Ballroom	2:00 PM	5:00 PM	2:15 PM	2:30 PM	2		Am Board of Int Medicine Maintenance of Certification Learning Session	Educational Session		Leukemia/stem cell transplant
Sat 12/7	Sonali	Smith		Hall F	7:30 AM	9:00 AM	8:00 AM	8:30 AM	2		Non-Hodgkin Lymphomas I: Optimizing Therapy	Educational Session		Dissecting follicular lymphomas: High versus low risk
Sat 12/7	Andrew	Artz		Grand Salon 4 (Hilton)	11:15 PM	12:15 PM	11:15 PM	12:15 PM	1			How I Treat: Bringing Science to Clinical Dilemmas		Allogeneic transplant for high-risk myelodysplastic syndromes
Sat 12/7	Olatoyosi	Odenike		La Nouvelle Ballroom C	2:00 PM	3:30 PM	3:00 PM	3:30 PM	3		Myeloproliferative Diseases: It's Not Only About JAK	Educational Session		Beyond JAK inhibitor therapy in myelofibrosis
Sat 12/7	Andrew	Artz		New Orleans Theater AB	2:00 PM	3:30 PM	3:00 PM	3:30 PM	3		Allogeneic Transplant for High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia: Are We Improving Outcomes	Educational Session		Older patients/older donors: choosing wisely
Sat 12/7	Aparna	Vasanthakumar	Godley	Hall E	5:30 PM	7:30 PM	NA	NA	NA	501	Hematopoietic Stem and Progenitor Biology: Poster I	Poster	1194	Hematopoietic stem cell function is regulated by hormonal and epigenetic factors
Sat 12/7	Angela	Stoddart	Le Beau	Hall E	5:30 PM	7:30 PM	NA	NA	NA	603	Oncogenes and Tumor Suppressors: Poster I	Poster	1275	Retroviral insertional mutagenesis in Egr1+/- mice, haploinsufficient for a human del(5q) myeloid leukemia gene, develop myeloid neoplasms with proviral insertions in genes syntenic to
Sat 12/7	Andrew	Evens	Chiu	Hall G	5:30 PM	7:30 PM	NA	NA	NA	622	Non-hodgkin Lymphoma: Biology, excluding Therapy: Poster I	Poster	1762	The influence of lifestyle factors on tumor-related markers and the microenvironment in follicular lymphoma (FL): Novel interactions and collective impact on survival
Sat 12/7	Houda	Alachkar	Nakamura	Hall E	5:30 PM	7:30 PM	NA	NA		615	Acute Myeloid Leukemia: Therapy, excluding transplantation: Poster I	Poster	1459	Growth inhibitory function of a novel T-LAK cell-originated protein kinase inhibitor on FLT3-ITD positive acute myeloid leukemia (AML) cells
Sun 12/8	Andrew	Artz		New Orleans Theater AB	7:30 AM	9:00 AM	8:30 PM	9:00 PM	3		Allogeneic Transplant for High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia: Are We Improving Outcomes	Educational Session		Older patients/older donors: choosing wisely
Sun 12/8	Sonali	Smith		Hall F	7:30 AM	9:00 AM	8:00 AM	8:30 AM	2		Non-h-Hodgkin Lymphomas I: Optimizing Therapy	Educational Session		Dissecting follicular lymphomas: High versus low risk
Sun 12/8	Olatoyosi	Odenike		La Nouvelle Ballroom C	9:30 AM	11:00 AM	10:30 AM	11:00 AM	3		Myeloproliferative Diseases: It's Not Only About JAK	Educational Session		Beyond JAK inhibitor therapy in myelofibrosis
Sun 12/8	Giuseppe	Saglio	Larson	E3 (insided Hall E)	5:00 PM	6:30 PM	5:15 PM	5:30 PM	2	632	Chronic Myeloid Leukemia: Therapy: Key Clinical Updates	Oral Session	91	ERESTnd update: Nilotinib (NIL) vs Imatinib (IM) in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact
Sun 12/8	Greg	Malnassy	Stock	Hall E	6:30 PM	8:30 PM	NA	NA	NA	611	Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Posters II	Poster	2547	Comparison of deep sequencing and allele-specific oligonucleotide PCR methods for MRD quantitation in acute lymphoblastic leukemia and mantle cell lymphoma: CALGB 10403 and CALGB 5990 (Alliance)

ASH 2013 Annual Meeting
December 7-10; New Orleans Convention Center
University of Chicago Medicine Comprehensive Cancer Center Presentations

Sun 12/8	Jacoda	Jasielec	Jakubowiak	Hall G	6:30 PM	8:30 PM	NA	NA	NA	653	Myeloma: Therapy, excluding Transplantation: Poster II	Poster	3220	Predictors of treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in newly diagnosed multiple myeloma (NDMM)
Sun 12/8	Noreen	Fulton	Stock	Hall G	6:30 PM	8:30 PM	NA	NA	NA	622	Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster II	Poster	3002	Minimal residual disease (MRD) status following induction chemotherapy predicts progression-free survival in mantle cell lymphoma (MCL): CALGB 50403 (Alliance)
Sun 12/8	Chadi	Nabhan		Hall G	6:30 PM	8:30 PM	NA	NA	NA	624	Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II	Poster	3058	A proposed prognostic model for overall survival in the oldest old (>80 years old) follicular lymphoma patients
Mon 12/9	Shaun	Rosebeck	Jakubowiak	391-392	7:00 AM	8:30 AM	7:30 AM	7:45 AM	3	652	Myeloma: Pathophysiology and Pre-clinical Studies, excluding Therapy: Drug Resistance	Oral Session	279	Effects of inhibition of SPO1/CRM1-dependent nuclear export by selinexor (KPT-330), alone and in combination with carfilzomib (CFZ), on apoptosis and autophagy in multiple myeloma (MM)
Mon 12/9	Christopher	Daugherty		211-212	10:30 AM	12:00 PM			Co-chair		Transition Point in Hematological Malignancies: What to Do When Cure is No Longer Possible	Education Spotlight		
Mon 4/2	Colles	Price	Chen	Hall E	6:00 PM	8:00 PM	NA	NA	NA	602	Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III	Poster	3740	MLL-rearranged acute myeloid leukemias drive expression of miR-9, a critical oncogene in leukemogenesis
Mon 4/2	Anjali	Advani	Stock	Hall G	6:00 PM	8:00 PM	NA	NA	NA	614	Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III	Poster	3093	Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US intergroup trial C10403 (Alliance)
Mon 4/2	Gottfried	von Keudell	Kline	Hall G	6:00 PM	8:00 PM	NA	NA	NA	722	Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune Reconstitution: Poster III	Poster	4607	Pilot study of regulatory T cell depletion in the setting of autologous stem cell transplantation for multiple myeloma
Mon 4/2	Lori	Muffy	Daugherty				6:45 PM	7:00 PM	3	901	Health Services and Outcomes Research: Guidelines and Practice Gaps, Survivorship and Quality of Life	Oral Session	771	Suffering before the cure: evaluation of psychological morbidities in adolescents and young adults with hematologic malignancies in early survivorship